EASTON BIOPHARMACEUTICALS: The company's hydrochloride deoxycorticosterone injection and beraprost sodium tablets are expected to be selected for national centralized drug procurement

Zhitong
2025.10.28 09:05

EASTON BIOPHARMACEUTICALS announced that on October 27, 2025, the company participated in the bidding organized by the National Organization for Drug Procurement Office for the 11th batch of national centralized drug procurement. The company's products, hydrochloride deoxycorticosterone injection and beraprost sodium tablets, are expected to be selected for this centralized procurement. Hydrochloride deoxycorticosterone injection is used to treat clinical hypotension caused by vasodilation during anesthesia, with a specification of 5ml: 0.5mg1 vial, and the expected selected price is 1.35 yuan/vial, with a procurement period until December 31, 2028. Beraprost sodium tablets are used to improve symptoms such as ulcers, intermittent claudication, pain, and cold sensation caused by chronic arterial occlusive disease, with a specification of 20ug30 tablets*1 box, and the expected selected price is 13.98 yuan/box, with a procurement period until December 31, 2028

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.